QR код

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

Purpose To evaluate whether administration of the oral DNA hypomethylating agent CC-486 enhances the poor response rate of immunologically ‘cold’ solid tumors to immune checkpoint inhibitor durvalumab.Experimental design PD-L1/PD-1 inhibitor naïve patients with advanced microsatellite stable colorec...

Повний опис

Збережено в:
Автори: Neda Stjepanovic, Amit M Oza, Anna Spreafico, Stephanie Lheureux, Marcus O Butler, Pamela S Ohashi, Kirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, Ben Wang, Shu Yi Shen, Ilias Ettayebi, Charles A Ishak, Philippe L Bedard, Albiruni Abdul Razak, Aaron R Hansen, Dave Cescon, Brendan Van As, Sarah Boross-Harmer, Lisa Wang, Trevor J Pugh, Lillian L Siu, Daniel D De Carvalho
Формат: Artigo
Мова:Inglês
Опубліковано: BMJ Publishing Group 2020-10-01
Серія:Journal for ImmunoTherapy of Cancer
Онлайн доступ:https://jitc.bmj.com/content/8/2/e000883.full
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси